“Antibody-Drug Conjugates (ADC)”

Filter

15 of 3,901

Sort

ABBVAbbVie Inc.🔥

Healthcare · Pharmaceuticals

$402.35B-1.1%

P/E 110.5·P/S 6.4·Mgn 5.8%·ROE —·FCF 4.4%

F 7

MRKMerck & Co., Inc.⚡

Healthcare · Pharmaceuticals

$294.03B-0.7%

P/E 32.9·P/S 4.5·Mgn 13.6%·ROE 34.7%·FCF 4.2%

F 4

EXELEXELIXIS, INC.

Healthcare · Biotechnology

$13.35B+0.2%

P/E 25.6·P/S 6.2·Mgn 24.0%·ROE 36.2%·FCF 6.6%

F 6

Red 8-K

RVTYREVVITY, INC.🔥

Healthcare · Diagnostics & Tools

$11.12B+0.0%

P/E 46.1·P/S 3.9·Mgn 8.4%·ROE 3.3%·FCF 4.6%

—

IMNMImmunome Inc.

Healthcare · Pharmaceuticals

$2.08B+0.7%

P/E —·P/S 518.4·Mgn -5593.8%·ROE -33.5%·FCF -9.6%

—

ZYMEZymeworks Inc.

Healthcare · Pharmaceuticals

$1.68B+8.5%

P/E —·P/S 20.7·Mgn -126.3%·ROE -30.2%·FCF -2.1%

—

AVBPArriVent BioPharma, Inc.

Healthcare · Pharmaceuticals

$1.42B+1.1%

P/E —·P/S —·Mgn —·ROE -54.1%·FCF —

—

CERTCertara, Inc.

Technology · Software

$809M+3.0%

P/E —·P/S 1.9·Mgn -3.6%·ROE -0.2%·FCF 11.7%

—

Red 8-K

CTMXCytomX Therapeutics, Inc.

Healthcare · Pharmaceuticals

$655M+0.3%

P/E —·P/S 18.4·Mgn -166.4%·ROE -17.5%·FCF -11.6%

—

Red 8-K

STROSUTRO BIOPHARMA, INC.

Healthcare · Biotechnology

$477M-0.5%

P/E —·P/S 4.8·Mgn -154.2%·ROE —·FCF —

—

MGNXMACROGENICS INC

Healthcare · Pharmaceuticals

$252M-4.9%

P/E —·P/S 1.6·Mgn -44.8%·ROE -134.2%·FCF -33.0%

F 3

WHWKWhitehawk Therapeutics, Inc.

Healthcare · Pharmaceuticals

$206M+3.9%

P/E —·P/S 28.8·Mgn -288.3%·ROE -15.1%·FCF -47.6%

F 4

13DDilut.

HURATuHURA Biosciences, Inc./NV

Healthcare · Pharmaceuticals

$148M+2.2%

P/E —·P/S —·Mgn —·ROE -143.6%·FCF -18.8%

—

Dilut.Red 8-K

PYXSPyxis Oncology, Inc.

Healthcare · Pharmaceuticals

$112M+5.2%

P/E —·P/S 8.0·Mgn -589.8%·ROE -149.1%·FCF -57.0%

F 2

Red 8-K

OSTXOS Therapies Inc

Healthcare · Pharmaceuticals

$76M-15.2%

P/E —·P/S —·Mgn —·ROE —·FCF —

—

Dilut.

Filings · filterAll 10-K 10-Q 8-K S-1 DEF 14A SC 13D

Filings

40 shown

BRLSWBorealis Foods Inc.

10-Q

Quarterly report — three-month financials and management discussion.

Jun 30, 2026·18h ago

PRPHProPhase Labs, Inc.

10-Q

Quarterly report — three-month financials and management discussion.

Companies above the $50M market cap · $1 pricefloor; SPAC/shells hidden by default. Fundamentals & prices via Polygon · signals from SEC EDGAR — verify on SEC.gov. Filings current to Jun 30 · prices to Jun 30.